JPRN-UMIN000014259招募中未知
Cohort study of FOLFIRINOX as third-line chemotherapy for metastatic pancreatic cancer. - Cohort study of FOLFIRINOX as third-line chemotherapy for metastatic pancreatic cancer.
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) active synchronous or metachronous malignancy other than carcinoma in situ 2) pregnant or nursing 3) severe mental disorders 4) serious coexisting illness 5) other medical condition unacceptable for entry
研究者
相似试验
已完成
2 期
Second-line chemotherapy FOLFIRINOX in unresectable cholangiocarcinomacholangiocarcinomaBile duct and gallbladder cancer10019815NL-OMON42542Academisch Medisch Centrum30
已完成
不适用
A randomized phase III study of modified FOLFIRINOX (5-FU/LV, irinotecan, and oxaliplatin) versus S-1 alone chemotherapy as second-line chemotherapy for gemcitabine-failed metastatic pancreatic cancerKCT0003534Gyeongsang National University Hospital80
进行中（未招募）
1 期
PREOPANC-5Pancreatic cancer, Borderline resectable pancreatic cancer (BRPC)CTIS2023-508707-20-00Amsterdam UMC66
已完成
不适用
Phase I study of third-line FOLFIRINOX (oxaliplatin, irinotecan, 5-FU, and leucovorin) unresectable Gem/S-1 refractory pancreatic adenocarcinomaunresectable Gem/S-1 refractory pancreatic adenocarcinomaJPRN-UMIN000021526Osaka Medical Center for Cancer and Cardiovascular Diseases Division of Hepatobiliary and Pancreatic Oncology60
Unknown
2 期
Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and OxaliplatinColorectal Cancer Stage IVNCT05354817Instituto do Cancer do Estado de São Paulo25